ICON to Expand Hospital-based Presence for Translational Medicine
ICON plc
, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced plans to further expand its UK hospital-based presence on the Manchester Royal Infirmary Campus. ICON has secured a 40,000 square foot pre-let at Citylabs, a newly developed biomedical centre of excellence which was formerly the Manchester Royal Eye Hospital.
ICON currently operates a state-of-the-art, hospital-based Clinical Pharmacology Unit on the Manchester Royal Infirmary Campus, where it will continue to run its Phase I operations until fully transitioning into the new, larger Citylabs facility, currently targeted to open in Q4 2013. Along with ICON's Translational Medicine Research Centre, Citylabs will feature biohealth organisations, including the Central Manchester University Hospitals NHS Foundation Trust, The University of Manchester and other commercial research organisations.
“We are pleased to be expanding our early phase development services through the establishment of a Centre of Excellence for Translational Medicine in Citylabs,” commented Dr. Mario Rocci, President, ICON Development Solutions. “This expansion will enable ICON to increase the capacity of its Clinical Pharmacology Unit in Manchester as well as the scientific services that are essential in providing a world class offering.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
